Core Viewpoint - The collaboration between 康哲药业 and Novartis Pharma Services AG aims to enhance the competitive edge of 康哲维盛 in the ophthalmology sector through exclusive rights for the import, distribution, and promotion of two key products in mainland China [1][2] Group 1: Agreement Details - 康哲药业 has signed a distribution agreement with Novartis for 雷珠单抗注射液 (诺适得) and 布西珠单抗注射液 (倍优适) [1] - The agreement grants 康哲药业 exclusive rights for import, distribution, sales, and promotion in mainland China, while Novartis will continue to handle production and supply [1] - The duration of the collaboration is set for five years from the effective date of the agreement [1] Group 2: Impact on Business - The partnership is expected to enhance 康哲维盛's overall competitiveness in the ophthalmology field, which already covers conditions such as retinal diseases, visual fatigue, and glaucoma [2] - The introduction of 诺适得 and 倍优适 will synergize with existing products like the exclusive drug 施图伦滴眼液 and the EyeOP1 glaucoma treatment device, improving academic brand competitiveness [2] - 康哲维盛's specialized ophthalmology team will integrate market channels and academic resources, leading to improved overall team efficiency and a positive impact on the company's performance [2]

Core Insights - 康哲药业 has signed a distribution agreement with Novartis for the exclusive import, distribution, sales, and promotion rights of two ophthalmic products in mainland China, which is expected to enhance its competitiveness in the ophthalmology sector and positively impact its performance [1][2] Group 1: Agreement Details - The agreement grants 康哲药业 exclusive rights for 雷珠单抗注射液 ("诺适得") and 布西珠单抗注射液 ("倍优适") in China for a duration of five years, while Novartis will continue to handle production and supply [1] - Both products are already approved for sale in China, with "诺适得" being the first anti-VEGF drug approved for ophthalmology in the country and "倍优适" being the smallest molecular weight anti-VEGF drug [1][2] Group 2: Market Context - "诺适得" is approved for multiple retinal neovascular diseases, including wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), and was included in the National Basic Medical Insurance Drug List in 2017 [2] - "倍优适" is expected to be approved for DME by May 2025, with an estimated 7.89 million DME patients in China by that year, indicating a strong demand for effective treatment options [2] - The collaboration is anticipated to create synergies with existing products in 康哲维盛's portfolio, enhancing its market presence in various ophthalmic conditions [2]